TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14767084
Drug: Oral deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral deferiprone (L1) at a dose of 75 mg/kg/day
Study: 14767084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daily L1 at a dose of 75 mg/kg/day and DFX at a dose of 40 mg/kg/day two times per week
Study: 11577795
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with gabexate
Study: 11577795
Drug: Prophylactic antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antifungal therapy
Study: 11577795
Drug: Pharmacotherapy focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy focusing on suppression of pro-inflammatory cytokines
Study: 9285295
Drug: IFN-beta 1b
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta 1b (Betaseron) treatment
Study: 8123056
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2 and 65% O2 for 30 seconds
Study: 3779921
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (152 patients) or intracoronary streptokinase preceded by intravenous streptokinase (117 patients)
Study: 3779921
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (264 patients)
Study: 28124799
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills training (8 weekly 2-hour sessions including cooperation, assertion, social cognitive problem solving strategies, role playing, games, and arts and crafts)
Study: 24720731
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) administration
Study: 19222764
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg intravenous bolus followed by continuous infusion of 20 microg kg(‐1) h(‐1))
Study: 8016770
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 500 micrograms four times daily
Study: 8016770
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 1000 micrograms four times daily
Study: 8016770
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 1500 micrograms four times daily
Study: 31609072
Drug: Avocatin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocatin B (AvoB) 50 mg per day for 60 days
Study: 31609072
Drug: Avocatin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocatin B (AvoB) 200 mg per day for 60 days
Study: 25340383
Drug: Maximal medical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal medical therapy plus LVRS
Study: 21380990
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral micronized progesterone (MP) 400 mg
Study: 9386146
Drug: 17beta-estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (1 mg sublingual)
Study: 7938102
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (P) treatment (group 1)
Study: 24146219
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal doxorubicin and intravenous rituximab (500 mg/m² twice/cycle) in CODOX-M/IVAC regimen
Study: 9113347
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of melanotan-I at a dose of 0.16 mg/kg
Study: 9113347
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of melanotan-I at doses from 0.08 to 0.21 mg/kg
Study: 9113347
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) administration of melanotan-I at a dose of 0.16 mg/kg
Study: 25417402
Drug: Liandouqingmai recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liandouqingmai recipe plus standard treatment for CHD
Study: 16896508
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg daily for 3 days, total 90 mg)
Study: 14662571
Drug: 2-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-component acellular vaccine
Study: 14662571
Drug: 5-component pertussis
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-component pertussis vaccine
Study: 14662571
Drug: whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: whole cell pertussis vaccine
Study: 14662571
Drug: diphtheria and
Normalized name: Diphtheria and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphtheria and tetanus toxoids vaccine alone
Study: 14662571
Drug: 2-component pertussis
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-component pertussis vaccine with booster
Study: 14662571
Drug: any of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: any of the vaccines
Study: 1603140
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg of calcium citrate malate per day)
Study: 3894128
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (pump treatment)
Study: 23707680
Drug: Perceived treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived treatment allocation (active vs placebo)
Study: 12885807
Drug: Monthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regimen of fluorouracil and leucovorin (FULV)
Study: 11475269
Drug: Repaglinide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 0.25 mg
Study: 11475269
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 mg
Study: 1877851
Drug: MaxEPA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxEPA (eicosapentaenoic acid) 20 g daily
Study: 1877851
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (placebo) 20 g daily
Study: 6781613
Drug: Oestradiol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol 150 mg
Study: 6781613
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) 4 mg
Study: 16422961
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 1 mL bimix (30 mg papaverine + 1 mg phentolamine) followed by 1 mL mixture of papaverine and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine)
Study: 16422961
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 1 mL trimix (30 mg papaverine + 1 mg phentolamine + 10 microg PGE1) followed by 1 mL mixture of papaverine, PGE1, and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine + 10 microg PGE1)
Study: 16422961
Drug: Various intracavernous
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various intracavernous injections of chlorpromazine in doses 1 mg, 2 mg, 5 mg, and 10 mg
Study: 11883914
Drug: Chocolate condition
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate condition (CC, N=13)
Study: 8590553
Drug: Beta-adrenergic receptor
Normalized name: Beta-adrenergic receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic receptor blockade (propranolol)
Study: 8590553
Drug: Lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusion with propranolol
Study: 2498781
Drug: Salbutamol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.5 mg i.v. in 15 min (Group A)
Study: 2498781
Drug: Glucose 40
Normalized name: glucose 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 40 g i.v. plus 10 units insulin i.v. in 15 min (Group B)
Study: 2498781
Drug: Salbutamol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.5 mg i.v., glucose 40 g i.v. and insulin 10 units i.v. over 15 min (Group C)
Study: 31212041
Drug: Spaced instruction
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spaced instruction (four weekly sessions)
Study: 31212041
Drug: Massed instruction
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed instruction (two sequential days)
Study: 25384419
Drug: Self-management Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management Acceptance and Commitment Therapy-based training intervention (ACTr)
Study: 21804337
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (8 sessions, twice a week for 60 minutes each)
Study: 14969665
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive system (Ortho Evra)
Study: 14969665
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive system (Ortho Evra) and Oral contraceptive (OC)
Study: 12475842
Drug: INS316 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS316 (10 to 180 mg)
Study: 9649975
Drug: Fluoxetine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (in severe depression subsample)
Study: 2589361
Drug: Intravenous/oral ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral ciprofloxacin
Study: 25529410
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation (ES) following Botulinum Toxin A (BoNT/A) injection
Study: 25529410
Drug: Control (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (only daily stretch)
Study: 14768494
Drug: Selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective beta-blockers
Study: 1873013
Drug: Intravenous norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous norepinephrine (NE) infusion
Study: 26660722
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription
Study: 28459237
Drug: Jinshuibao capsules
Normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinshuibao capsules (JCs)
Study: 25106092
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight barley β‐glucan (3 g)
Study: 25106092
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight barley β‐glucan (3 g)
Study: 22071249
Drug: Intradermal IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal IPV (GlaxoSmithKline)
Study: 22071249
Drug: Intramuscular IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular IPV (GlaxoSmithKline)
Study: 22071249
Drug: Intramuscular IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular IPV (Panacea)
Study: 22071249
Drug: Intradermal IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal IPV
Study: 22071249
Drug: Intramuscular IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular IPV
Study: 19671190
Drug: Artemisinin-naphthoquine combination
Normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine combination (ANQ)
Study: 19671190
Drug: Chloroquine plus
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine plus single dose sulphadoxine-pyrimethamine (CQ+SP)
Study: 16113582
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Study: 30137415
Drug: GH/GnRHa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH/GnRHa treatment
Study: 15620935
Drug: Intravenous isoxazolyl-penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isoxazolyl-penicillin alone (control group)
Study: 2191588
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (after initial monotherapy)
Study: 6999546
Drug: PGE2-gel (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2-gel (0.05 mg, 3 ml)
Study: 6999546
Drug: gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel without PGE2
Study: 26066587
Drug: High ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High ascorbate group (HA) with plasma ascorbate levels >1 mmol/l
Study: 26066587
Drug: Low ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low ascorbate group (LA) with plasma ascorbate levels <1 mmol/l
Study: 21028984
Drug: CHG-impregnated cloths
Normalized name: CHG Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHG-impregnated cloths applied thrice weekly
Study: 21028984
Drug: Control cloths
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cloths (Comfort Bath; Sage) applied thrice weekly
Study: 11595689
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine with gp100(280) peptide and tetanus helper peptide
Study: 9678294
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen 2.5 mg
Study: 9678294
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen 5 mg
Study: 8270757
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g added barley bran flour
Study: 8270757
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g added barley oil extract
Study: 8270757
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g added cellulose (control)
Study: 2683024
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) chewable tablets at a dose of four tablets daily for 1 month
Study: 808195
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion at 1.7 gm/kg
Study: 808195
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion at 1.0 gm/kg
Study: 31618704
Drug: DPFC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPFC (cisplatin 40 mg/m2, docetaxel 40 mg/m2, 5-FU 2000 mg/m2, cetuximab 400/250 mg/m2)
Study: 31618704
Drug: PFC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFC (cisplatin 100 mg/m2, 5-FU 1000 mg/m2, cetuximab 400/250 mg/m2)
Study: 25218668
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day by week 4, n = 38)
Study: 24283058
Drug: T+M (2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+M (2g BID tinidazole for two days and vaginal suppositories of 1000 mg metronidazole at day 1 and 3)
Study: 24283058
Drug: T+M+P (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+M+P (same as T+M plus topical administration of vaginal probiotic from day 5)
Study: 16957540
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation (VNS) + Electroconvulsive Therapy (ECT)
Study: 10227615
Drug: Topiramate 6
Normalized name: topiramate 69 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 6 mg/kg/day
Study: 1684909
Drug: D-verapamil (DVPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-verapamil (DVPM) 800 mg/day
Study: 1684909
Drug: D-verapamil (DVPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-verapamil (DVPM) 1200 mg/day
Study: 1684909
Drug: D-verapamil (DVPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-verapamil (DVPM) 600 mg/day
Study: 1684909
Drug: D-verapamil (DVPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-verapamil (DVPM) 150-300 mg 6 h
Study: 7043162
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 g GABA (intervention)
Study: 7043162
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg muscimol (intervention)
Study: 25091663
Drug: 116E rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 116E rotavirus vaccine
Study: 17317370
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg + Ezetimibe 10 mg
Study: 11274548
Drug: Triple-dose gadodiamide
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose gadodiamide (0.3 mmol/kg)
Study: 11274548
Drug: Single-dose gadodiamide
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose gadodiamide (0.1 mmol/kg)
Study: 9737831
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid 20% cream and glycolic acid lotion
Study: 7913292
Drug: eformoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: eformoterol 24 micrograms twice daily
Study: 21144515
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (200 μg)
Study: 18295465
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release Ikorel tablet
Study: 16863527
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 100 mg three times per day
Study: 12645862
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lignocaine
Study: 12645862
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lignocaine
Study: 11289670
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (200,000 IU, 2 doses at baseline, additional doses at 4 and 8 months)
Study: 9316621
Drug: rhIL-1 beta
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-1 beta (all dose levels)
Study: 8451780
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 300 mg
Study: 3092053
Drug: Diazepam (tapered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (tapered doses)
Study: 30830119
Drug: Choline alfoscerate
Normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline alfoscerate (ChA) 14 mg/kg
Study: 30830119
Drug: Succinate combination
Normalized name: succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinate combination (SC) 0.5 mg/kg
Study: 30830119
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ChA and SC
Study: 27062963
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea extract (GTE) 1500 mg daily for 4 weeks
Study: 23200974
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% lignocaine jelly
Study: 20739853
Drug: Good glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good glucose control (target glucose level of 130 mg/dL)
Study: 20739853
Drug: Poor glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor glucose control (glucose levels above 130 mg/dL)
Study: 28438257
Drug: Test allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test allopurinol tablet (300 mg)
Study: 28438257
Drug: Reference allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference allopurinol tablet (300 mg)
Study: 8840352
Drug: Arecoline 1
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 1 mg/day
Study: 8840352
Drug: Arecoline 4
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 4 mg/day
Study: 8840352
Drug: Arecoline 16
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 16 mg/day
Study: 8840352
Drug: Arecoline 28
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 28 mg/day
Study: 8840352
Drug: Arecoline 40
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 40 mg/day
Study: 1751666
Drug: Fibrous carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrous carbon enterosorbent VESTA in tablets for 14 days (group I)